TROP2 CAR/IL-15 TGFBR2 KO NK cell therapy for oral precancerous lesions
Part of Cancer clinical trials.
This early-phase study tests an experimental cell therapy for people with oral precancerous lesions. The therapy uses immune cells engineered to target and destroy abnormal cells in the mouth, potentially preventing them from becoming cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed oral precancerous lesion (dysplasia) or a history of oral cancer with new lesions.
- Your lesion must show a certain protein (TROP2) on biopsy.
- You must be at least 18 years old.
- You must have good overall health (ECOG 0-1) and adequate organ function.
- You must be willing to travel to the study site (within 2 hours' drive) for the first month of treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
This early-phase trial tests a new type of immune cell therapy combined with radiation for advanced head and neck cancer. The cells are engineered to target the TROP2 marker on cancer cells and are given after a short course of radiation to help them work better.
This trial tests a new treatment that combines a type of immune cell called NK cells with a targeted drug called T-Dxd for people with advanced breast cancer that has stopped responding to other treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests a new type of CAR-T cell therapy that targets a protein called Trop2 found on some head and neck cancer cells. It's for people who have tried standard treatments and need a new option.
This trial tests an investigational cell therapy called Trop2 CAR-NK for people with advanced non-small cell lung cancer that has come back after standard treatments. The therapy uses your own immune cells (natural killer cells) that are specially trained to find and attack cancer cells that carry the Trop2 protein. This may help shrink tumors or slow the cancer's growth.
This Phase 2 trial tests a chemotherapy plan given first (before surgery) for people with oral squamous cell carcinoma that has specific cancer markers and lymph node involvement. It aims to shrink or control the cancer so treatment after may work better.
Hear when a new Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.